Remove tag digital-care
article thumbnail

BD partners with Biocorp on connected self-injection devices

pharmaphorum

Medtech giant Beckton Dickinson (BD) has signed a deal with France’s Biocorp to use the latter’s near-field communication (NFC) tags in injectable devices. The Injay tag can confirm a complete injection and transfer that information via an NFC reader to a smartphone or tablet for review by a healthcare professional.

article thumbnail

Grand Rounds February 23, 2024: Virtual Vigilance: Monitoring of Decentralized Clinical Trials (Adrian Hernandez, MD; Christopher J. Lindsell, PhD)

Rethinking Clinical Trials

Consider secure digital identification, two-fact authentication or virtual/video visits. Outcomes including patient reported outcomes, functional assessments including via digital technology, healthcare events or mortality may require identify verification. What we often do not think about is verifying the identity of the participant.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds October 21, 2022: Disinformation, Cyberthreat, and Choice: Protecting Patients and Clinical Research From the Digital Triple Threat (Eric Perakslis, PhD; Andrea Downing)

Rethinking Clinical Trials

Chief Science & Digital Officer. Health care and the internet are intertwined. Perakslis said his definition of digital health is any time you mix medical information and the internet. Should social media for teenagers be regulated like a digital therapeutic, given how addictive they are and the behavior modification.

article thumbnail

Jolly Good/Teijin Pharma develop VR digital therapeutics for depression

pharmaphorum

Technology firm Jolly Good and Teijin Pharma have begun a partnership to develop virtual reality digital therapeutics (VR DTx) for major depressive disorder. It also develops services to support the evolution of medical care and finding purposes in life, in collaboration with various research institutions and companies.

article thumbnail

Grand Rounds March 3, 2023: Adoption, Implementation and Sustainment of Family-focused Prevention in Health Care Systems: How Do We Get There? (Margaret Kuklinski, PhD; Stacy Sterling, DrPH, MSW)

Rethinking Clinical Trials

GGC4H is a 5-year, longitudinal cluster-randomized trial that took place in pediatric primary care. The study offered GGC to all caregivers in the intervention arm, using 2 modalities, virtual groups and digital self-guided. 3) Is virtual GGC satisfying to parents and 4) What do health care system leaders say?

article thumbnail

Grand Rounds June 30, 2023: Decentralized Trials – From Guidance to Reality & What’s Left (Adrian Hernandez, MD, MHS; Pamela Tenaerts, MD, MPH; Craig Lipset, MPH)

Rethinking Clinical Trials

For instance, there is no discussion of the role of the health care provider in the DCTs, but it emphasizes the importance of patient voice. The key remaining issues for DCTs include clarification around the roles and responsibilities of health care providers as well as principal investigator (PI) oversight and responsibility.

Trials 130
article thumbnail

Grand Rounds February 2, 2024: Strategies for Improving Public Understanding of FDA and the Products It Regulates…Why Should We Care, and What Might We Do? (Susan C. Winckler, RPh, Esq)

Rethinking Clinical Trials

This work is important because the digital health information environment and limited public trust in government institutions represent pressing challenges for FDA. Potential strategy: Increase regular communication with health care professionals. Observation 5: Consistent, multi-channel messages resonate with consumers.